Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 7, 2024; 30(9): 1250-1252
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1250
Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective
James Guoxian Huang
James Guoxian Huang, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Khoo Teck Puat-National University Children’s Medical Institute, National University Health System, Singapore 119228, Singapore
James Guoxian Huang, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore
Author contributions: Huang JG wrote the letter; and Huang JG revised the letter.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: James Guoxian Huang, MBBS, MRCP, Assistant Professor, Doctor, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Khoo Teck Puat-National University Children’s Medical Institute, National University Health System, NUHS Tower Block Level 12, 1E Kent Ridge Road, Singapore 119228, Singapore. paehgj@nus.edu.sg
Received: November 11, 2023
Peer-review started: November 11, 2023
First decision: January 5, 2024
Revised: January 8, 2024
Accepted: February 5, 2024
Article in press: February 5, 2024
Published online: March 7, 2024
Core Tip

Core Tip: Polygenic scoring models may determine an inflammatory bowel disease patient’s actual risk for venous thromboembolism (VTE) with greater accuracy than monogenic screening alone. This may be due to the cumulative effect of multiple pro-thrombotic genetic loci having a greater influence on thrombotic risk, rather than specific genetic mutations. There needs to be cross-validation of such scoring models in ethnically diverse populations as there is significant heterogeneity in the prevalence of genes implicated in thrombophilia. A composite score combining clinical and polygenic risk factors would further enhance the accuracy in determining one’s VTE risk.